Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381732 | 0.87 | RIPK1 (0.59) | FGFR1GSK3BHPGDALDH1A1RIPK1 | |
| SCHEMBL1381279 | 0.87 | MAOB (0.64) | FGFR1GSK3BPARP10MAOBHPGD | |
| SCHEMBL1379253 | 0.87 | MAPT (0.50) | FGFR1GSK3BHPGDALDH1A1RIPK1 | |
| SCHEMBL1378146 | 0.84 | HPGD (0.63) | GSK3BHPGDALDH1A1RIPK1RIPK3 | |
| SCHEMBL1378500 | 0.83 | FGFR1 (0.53) | FGFR1GSK3BPARP10MAOBHPGD | |
| SCHEMBL1378232 | 0.81 | MAPT (0.51) | HPGDALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL1378402 | 0.80 | KMT2A (0.46) | GSK3BHPGDALDH1A1RIPK1RIPK3 | |
| SCHEMBL1380637 | 0.79 | L3MBTL1 (0.54) | FGFR1HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL25999599 | 0.78 | PARP10 (0.50) | FGFR1PARP10MAOBMEN1KMT2A | |
| SCHEMBL4492204 | 0.78 | FGFR1 (0.57) | FGFR1GSK3BMAOBHPGDRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4769720-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | claimed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | FGFR1 912/4885GSK3B 1424/4885PARP10 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.